Clinical Trials Browser

Not yet recruiting × Lung Neoplasms × osimertinib × Clear all

NCT07486648 2026-03-24

Precision

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07285148 2025-12-16

A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06918782 2025-04-09

Real-world Experience With Combination Chemotherapy and Osimertinib in Poor Prognostic Group of Metastatic EGFR-mutated Lung Adenocarcinoma

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06530719 2024-07-31

A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06323148 2024-03-21

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

Phase 3 Not yet recruiting

Lung Neoplasms, Neoplasm, Residual

NCT06067776 2023-10-05

Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer

Phase 1 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms